Results 71 to 80 of about 8,581 (194)

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

A Revised Model for Muscarine Biosynthesis Involving Lysine Trimethylation

Angewandte Chemie, Volume 138, Issue 24, 8 June 2026.
The fatal mushroom toxin l‐(+)‐muscarine is one of the most prominent natural products. We elucidated its biosynthetic origin in the sweating mushroom Collybia rivulosa based on incorporation of stable isotope‐labeled compounds and extensive mass spectrometric analyses.
Sebastian Dörner, Kai Rogge, Felix Trottmann, Christian Hertweck, Dirk Hoffmeister   +4 more
wiley   +2 more sources

Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats

Translational Psychiatry
Psilocybin has shown promise as a novel pharmacological intervention for treatment of depression, where post-acute effects of psilocybin treatment have been associated with increased positive mood and decreased pessimism.
Elizabeth L. Fisher, Ryan Smith, Kyna Conn, Andrew W. Corcoran, Laura K. Milton, Jakob Hohwy, Claire J. Foldi   +6 more
doaj   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Psilocybin-occasioned Mystical-Type Experiences and Mental Wellness

Psilocybin, the psychoactive compound found in certain mushrooms, has gained increasing attention for its potential therapeutic applications in mental health treatment. While clinical research highlights its efficacy in alleviating mental disorders, such
Romesha Uduwawela (22141375)
core   +1 more source

Oregon psilocybin business resource guide

, 2023
This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may not be suitable for legal purposes.Mode of access: Internet from the Oregon Government ...

core  

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Data_Sheet_1_Acute psilocybin increased cortical activities in rats.docx

, 2023
Psilocybin, a naturally occurring hallucinogenic component of magic mushrooms, has significant psychoactive effects in both humans and rodents. But the underlying mechanisms are not fully understood.
Junhong Liu (6839111), Danhao Zheng (15831821), Aoling Cai (15831824), Ruibin Su (2603443), Yuanyuan Wang (20181), Haitao Yan (291625), Ke Xia (303441), Jinfeng Wu (608446)   +7 more
core   +1 more source

Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats

Scientific Reports
Major depressive disorder (MDD) is a leading cause of disability that affects over 300 million people globally. Despite multiple antidepressant trials, approximately one-third of MDD patients remain symptomatic, progressing to treatment-resistant ...
Zitong Wang, Brett Robbins, Ryan Zhuang, Rebekah van Bruggen, Thaisa Sandini, Xin-Min Li, Yanbo Zhang   +6 more
doaj   +1 more source